A Novel Approach to Brain Tumor Therapy
Advisory Board member Tara Morrison, MD, a renowned expert in the treatment of brain cancer, reviews a novel brain tumor therapy.
Advisory Board member Tara Morrison, MD, a renowned expert in the treatment of brain cancer, reviews a novel brain tumor therapy.
Development of new targeted therapies is needed for the treatment of ALK-positive neuroblastoma, according to researchers.
Low-dose pegylated interferon therapy delays the time to disease progression in children with diffuse intrinsic pontine glioma (DIPG).
Combination chemotherapy including thalidomide and irinotecan is not adequately effective for the treatment of aplastic glioma.
A new genetic variant in the TP53 gene predicts susceptibility to the development of gliomas and may shed light on its etiology.
Perifosine shows activity against chemoresistant and radioresistant neuroblastoma.
Children <15 years of age exposed to radiation from two to three CT scans to the head may have triple the risk of developing brain cancer, while five to ten scans can triple the risk of developing leukemia.
Patients with anaplastic oligodendroglioma with co-deletion for chromosomes 1p and 19q survive significantly longer after receiving chemotherapy immediately prior to radiotherapy, according to long-term follow-up of a randomized phase 3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
In glioblastoma, surviving for two years linked to favorable conditional probability of survival.